Compare
Solventum Corp vs Baxter International Inc vs ResMed Inc vs Dexcom Inc
| Latest fiscal year | Solventum Corp SOLV | Baxter International Inc BAX | ResMed Inc RMD | Dexcom Inc DXCM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $8.32B | $11.24B | $5.65B | $4.66B |
| Revenue growth (YoY) | +0.9% | +5.7% | +9.9% | +15.6% |
| Gross margin | 53.5% | 30.1% | 61.1% | 60.1% |
| Operating margin | 26.2% | -2.7% | 33.4% | 19.6% |
| Net margin | 18.7% | -8.5% | 26.9% | 17.9% |
| Net income | $1.56B | -$957.00M | $1.52B | $836.30M |
| EPS (Diluted) | $8.88 | -$1.87 | $10.43 | $2.09 |
| Operating cash flow | $369.00M | $845.00M | $1.81B | $1.44B |
| Free cash flow | -$10.00M | $332.00M | $1.65B | $1.08B |
| Cash & equivalents | $878.00M | $1.97B | $1.47B | $917.70M |
| Total assets | $14.29B | $20.05B | $8.97B | $6.34B |
| Total liabilities | $9.24B | $13.95B | $2.38B | $3.59B |
| Shareholders' equity | $5.05B | $6.10B | $6.59B | $2.75B |
| Return on year-end equity | 30.8% | -15.7% | 23.1% | 30.5% |
| Shares outstanding | 173.49M | n/a | 144.24M | 384.80M |
Revenue, most recent five fiscal years
| Fiscal year | Solventum Corp | Baxter International Inc | ResMed Inc | Dexcom Inc |
|---|---|---|---|---|
| Latest | $8.32B Ended 2025-12-31 | $11.24B Ended 2025-12-31 | $5.65B Ended 2026-06-30 | $4.66B Ended 2025-12-31 |
| 1 year earlier | $8.25B Ended 2024-12-31 | $10.64B Ended 2024-12-31 | $5.15B Ended 2025-06-30 | $4.03B Ended 2024-12-31 |
| 2 years earlier | $8.20B Ended 2023-12-31 | $10.36B Ended 2023-12-31 | $4.69B Ended 2024-06-30 | $3.62B Ended 2023-12-31 |
| 3 years earlier | $8.13B Ended 2022-12-31 | $10.06B Ended 2022-12-31 | $4.22B Ended 2023-06-30 | $2.91B Ended 2022-12-31 |
| 4 years earlier | n/a | $12.15B Ended 2021-12-31 | $3.58B Ended 2022-06-30 | $2.45B Ended 2021-12-31 |